Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy

Supportive Care in Cancer

Volumn 15, Issue 4, 2007, Pages 417-426

  Herrstedt, J ^a,e   Sigsgaard, T C ^a   Nielsen, H A ^a   Handberg, J ^b   Langer, S W ^c   Ottesen, S ^d   Dombernowsky, P ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d ROSKILDE HOSPITAL   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiemetics; Metopimazine; Multiple cycles; Multiple day cisplatin; Tropisetron

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; METOPIMAZINE; PLACEBO; TROPISETRON;

ADULT; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; ISONIPECOTIC ACIDS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS, GERM CELL AND EMBRYONAL; VOMITING;

EID: 34247882113     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0158-y     Document Type: Article

References (30)

1. Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 13:80-84
2. Antiemetic subcommittee of the Multinational Association of Supportive Care in Cancer (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811-819
3. Herrstedt J, Aapro MS, Smyth JF et al (1998) Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6:204-214
4. van den Berkmortel F, de Wit R, de Rooy J, de Mulder P (2004) Osteonecrosis in patients with testicular tumours treated with chemotherapy. Neth J Med 62:23-26
5. Winquist EW, Bauman GS, Balogh J (2001). Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol 24:603-606
6. Haid M (1981) Steroid antiemesis may be harmful. N Engl J Med 304:1237
7. Marigini G, Murray S, Goldhirsch A (1996) The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. Ann Oncol 7:245-250
8. Moertel CG, Reitemeier RJ (1973) Controlled studies of metopimazine for treatment of nausea and vomiting. J Clin Pharmacol 13:283-287
9. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328:1076-1080
10. Herrstedt J, Sigsgaard T, Handberg J et al (1997) Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol 15:1690-1696
11. Lebeau B, Depierre A, GIiovanni et al (1997) The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. Ann Oncol 8:887-892
12. 3 antagonist prophylaxis is not maintained. J Clin Oncol 14:644-651
13. Blijham GH (1992) Does granisetron remain effective over multiple cycles? Eur J Cancer 28A (Suppl 1):S17-S21
14. Herrstedt J, Jørgensen M, Angelo HR (1990) The effect of food on serum concentrations of metopimazine. Br J Clin Pharmacol 30:237-243
15. Einhorn LH, Rapoport B, Koeller J et al (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13:112-116
16. Sigsgaard T, Herrstedt J, Handberg J, Kjær M, Dombernowsky P (2001) Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 19:2091-2097
17. Sigsgaard T, Herrstedt J, Andersen LJ et al (1999) Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. Br J Cancer 80:412-418
18. The Granisetron Study Group (1993) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. J Cancer Res Clin Oncol 119:555-559
19. Bremer K on behalf of the Granisetron Study Group (1992) A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. Eur J Cancer 28A:1018-1022
20. Sledge GW, Einhorn LH, Nagy C, House K (1992) Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524-2528
21. Noble A, Bremer K, Goedhals D et al (1994) A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 30A:1083-1088
22. Fox SM, Einhorn LH, Cox E et al (1993) Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391-2395
23. Räth U, Upadhyaya BK, Arechavala E et al (1993) Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 50:168-172
24. Italian Group for Antiemetic Research (1998) Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 16:2937-2942
25. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
26. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119
27. Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830
28. de Wit R, Herrstedt J, Rapoport B et al (2004) The oral NK1 antagonist aprepitant given with standard antiemetics provided protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III trials. Eur J Cancer 40:403-410
29. Herrstedt J, Muss HB, Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-1555
30. Roila F, Hesketh PJ, Herrstedt J (2006) The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28